- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LOTUS PHARMACEUTICALS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STADA ARZNEIMITTEL | - | - | Canson Capital Partners agiert als Federführender Finanzberater von Capvest bei der Akquisition von Stada und co-investiert über seinen Merchant Banking Arm | London (ots/PRNewswire) - STADA ist die sechste Private-Equity-Transaktion, bei der Canson als Finanzberater und Co-Investor auftrittCanson Capital Partners ("Canson") freut sich bekannt zu geben, dass... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 63,30 | +0,09 % | IONIS PHARMACEUTICALS INC - 8-K, Current Report | ||
| CSPC PHARMA | 0,842 | -1,13 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORISATION APPLICATION FOR PERTUZUMAB INJECTION ACCEPTED BY THE NMPA | ||
| SELLAS LIFE SCIENCES | 1,206 | -1,31 % | SELLAS Life Sciences GAAP EPS of -$0.06 beats by $0.02 | ||
| ACADIA PHARMACEUTICALS | 20,430 | -2,34 % | RBC senkt Kursziel für Acadia Pharmaceuticals wegen schwacher Medicaid-Nachfrage | ||
| CATALYST PHARMACEUTICALS | 19,680 | +1,03 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 469,10 | -1,74 % | John Paulson's hedge fund boosts Bausch Health, trims Madrigal in Q3 moves | ||
| METRIOPHARM | - | - | MetrioPharm gains orphan drug status from EMA for MP1032 | ||
| ENZON PHARMACEUTICALS | 0,042 | +10,53 % | ENZON PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | ||
| OPUS GENETICS | 1,464 | -3,17 % | Opus Genetics doses first patient in Best disease gene therapy trial | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - November 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 3,660 | +1,10 % | Citizens lowers Savara stock price target to $10 on dilution concerns | ||
| VIRACTA THERAPEUTICS | 0,090 | 0,00 % | NSE - Viracta Therapeutics, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| GALECTIN THERAPEUTICS | 4,900 | -5,77 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update | NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 5,540 | +5,32 % | Biodexa Pharmaceuticals Plc - F-1, Registration statement for certain foreign private issuers |
LOTUS PHARMACEUTICALS INC gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOTUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.